Published in Ann Rheum Dis on September 22, 2009
Inflammatory immune cell responses and Toll-like receptor expression in synovial tissues in rheumatoid arthritis patients treated with biologics or DMARDs. Clin Rheumatol (2013) 1.42
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 1.10
Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol (2013) 1.09
Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am (2010) 1.06
Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol (2011) 0.96
Shikonin inhibits maturation of bone marrow-derived dendritic cells and suppresses allergic airway inflammation in a murine model of asthma. Br J Pharmacol (2010) 0.92
Collagen induces maturation of human monocyte-derived dendritic cells by signaling through osteoclast-associated receptor. J Immunol (2015) 0.81
Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2. J Immunol (2014) 0.79
Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance. J Immunol Res (2016) 0.79
Interleukin 17 inhibits progenitor cells in rheumatoid arthritis cartilage. Eur J Immunol (2015) 0.77
Rheumatoid arthritis: Anti-TNF therapy for RA hinders function and survival of dendritic cells. Nat Rev Rheumatol (2010) 0.75
TNF-α promotes IFN-γ-induced CD40 expression and antigen process in Myb-transformed hematological cells. ScientificWorldJournal (2012) 0.75
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions. Clin Exp Immunol (2016) 0.75
Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway. Pharmaceuticals (Basel) (2010) 0.75
Clostridium difficile toxin B intoxicated mouse colonic epithelial CT26 cells stimulate the activation of dendritic cells. Pathog Dis (2015) 0.75
TNF Blockade Maintains an IL-10(+) Phenotype in Human Effector CD4(+) and CD8(+) T Cells. Front Immunol (2017) 0.75
Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay. PLoS One (2017) 0.75
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity (2013) 2.69
Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol (2007) 2.19
Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. Arthritis Care Res (Hoboken) (2014) 2.11
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2010) 2.08
Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol (2003) 2.05
The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis (2012) 2.03
Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum (2010) 1.86
Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant (2008) 1.85
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med (2013) 1.67
Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood (2002) 1.57
Integrated safety in tocilizumab clinical trials. Arthritis Res Ther (2011) 1.55
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov (2007) 1.45
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum (2011) 1.44
Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells. J Leukoc Biol (2008) 1.40
Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis (2013) 1.37
Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis (2010) 1.29
Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol (2011) 1.27
Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest (2014) 1.25
Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol (2010) 1.24
LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol (2008) 1.23
Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays. J Biol Chem (2002) 1.20
Anti-TNF therapy. Best Pract Res Clin Rheumatol (2011) 1.18
Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum (2012) 1.17
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet (2008) 1.16
Low-strength T-cell activation promotes Th17 responses. Blood (2010) 1.15
Sustained IL-12 signaling is required for Th1 development. J Immunol (2004) 1.15
Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther (2006) 1.13
A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J Immunol (2005) 1.12
FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. PLoS One (2012) 1.07
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis (2010) 1.06
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res Ther (2004) 1.04
Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci (2004) 1.03
A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. Ann Rheum Dis (2012) 1.02
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum (2008) 1.01
Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther (2012) 1.00
Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice. Arthritis Res Ther (2006) 0.99
Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. Ann Rheum Dis (2010) 0.99
Regulatory T cells and autoimmunity. Curr Opin Hematol (2009) 0.98
Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2009) 0.97
Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis (2010) 0.96
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol (2004) 0.95
Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. Hum Mutat (2012) 0.94
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis (2010) 0.93
Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. Arthritis Res Ther (2006) 0.91
Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. Hum Mol Genet (2002) 0.91
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics (2009) 0.91
High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis Rheum (2002) 0.90
The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. Arthritis Rheum (2006) 0.90
Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther (2013) 0.90
Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann Rheum Dis (2011) 0.90
Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required? Arthritis Res Ther (2013) 0.90
Profound invariant natural killer T-cell deficiency in inflammatory arthritis. Ann Rheum Dis (2010) 0.88
Treg cells in rheumatoid arthritis: an update. Curr Rheumatol Rep (2013) 0.87
Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol (2008) 0.87
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Ann Rheum Dis (2009) 0.87
CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Allergy Clin Immunol (2005) 0.86
Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Res Ther (2012) 0.86
Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort. Ann Rheum Dis (2011) 0.85
Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology (Oxford) (2011) 0.85
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther (2014) 0.85
Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat Rev Rheumatol (2011) 0.84
Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming. Transplantation (2009) 0.84
Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells. Transplantation (2008) 0.82
What can rheumatologists learn from translational cancer therapy? Arthritis Res Ther (2013) 0.82
Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenet Genomics (2010) 0.81
Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. Rheumatology (Oxford) (2012) 0.81
Tregs and rheumatoid arthritis. Acta Reumatol Port (2008) 0.81
T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice. Ann Rheum Dis (2006) 0.81
A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment. BMC Med (2014) 0.80
Neutrophil contribution to the crescentic glomerulonephritis in SCG/Kj mice. Nephrol Dial Transplant (2004) 0.80
Glomerulonephritis induced by methicillin-resistant Staphylococcus aureus infection that progressed during puerperal period. Clin Exp Nephrol (2007) 0.80
Angiotensin II receptor blockade ameliorates mesangioproliferative glomerulonephritis in rats through suppression of CTGF and PAI-1, independently of the coagulation system. Nephron Exp Nephrol (2006) 0.80
A novel paradigm for dendritic cells as effectors of cartilage destruction. Rheumatology (Oxford) (2009) 0.80
Disease activity and cognition in rheumatoid arthritis: an open label pilot study. Arthritis Res Ther (2012) 0.79
Treating to re-establish tolerance in inflammatory arthritis - lessons from other diseases. Best Pract Res Clin Rheumatol (2010) 0.79
R&D productivity rides again? Pharm Stat (2014) 0.79
Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis (2004) 0.78
Prospects for therapeutic tolerance in humans. Curr Opin Rheumatol (2014) 0.78
Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12 months. Clin Rheumatol (2011) 0.77
Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? Expert Opin Investig Drugs (2009) 0.77
Trafficking of QD-conjugated MPO-ANCA in murine systemic vasculitis and glomerulonephritis model mice. Microbiol Immunol (2007) 0.77
Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology (Oxford) (2009) 0.76
Unique TCR beta-subunit variable gene haplotypes in Africans. Immunogenetics (2002) 0.76
Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's disease. J Clin Endocrinol Metab (2012) 0.76
Fc gamma receptors are critical modulators of inflammation within the synovium: comment on the article by Blom et al. Arthritis Rheum (2004) 0.75
An international survey of physicians regarding clinical trials: a comparison between Kyoto University Hospital and Seoul National University Hospital. BMC Med Res Methodol (2013) 0.75
The choice of adjuvant determines the cytokine profile of T cells in proteoglycan-induced arthritis but does not influence disease severity. Immunology (2013) 0.75